Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.53 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332092 | 0.88 | PTGDR2 (0.48) | PTGDR2PPARAMEN1CYP1A2CYP3A4 | |
| SCHEMBL1332548 | 0.81 | PTGDR2 (0.71) | PTGDR2 | |
| SCHEMBL1332090 | 0.81 | PTGDR2 (0.51) | PTGDR2RORCPPARAMEN1CYP1A2 | |
| SCHEMBL1332617 | 0.80 | PTGDR2 (0.50) | PTGDR2MEN1MAPTKMT2ATTR | |
| SCHEMBL3928430 | 0.80 | PTGDR2 (0.50) | PTGDR2MAPTTTR | |
| SCHEMBL1333653 | 0.80 | PTGDR2 (0.58) | PTGDR2TTR | |
| SCHEMBL28330663 | 0.80 | PTGDR2 (0.58) | PTGDR2TTR | |
| SCHEMBL1333658 | 0.79 | PTGDR2 (0.52) | PTGDR2MAPTTTR | |
| SCHEMBL1331643 | 0.79 | PTGDR2 (0.54) | PTGDR2PPARAPPARG | |
| SCHEMBL27849129 | 0.77 | PTGDR2 (0.51) | PTGDR2TTRCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB | 2011-11-17 | — | — | US | disclosed |
| US-8003703-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293352-A1 | Phenoxiacetic acid derivatives | HRH2, HRH1, HCAR2 | PTGDR2 13/4885RORC 25/4885PPARA 430/4885 |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | HIF1A, HPD, HIF1AN | PTGDR2 256/4885RORC 275/4885PPARA 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.